- Home
- BRKL vs NTLA Comparison
BRKL vs NTLA Comparison
Compare BRKL & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKL
- NTLA
- Stock Information
- Founded
- BRKL 1871
- NTLA 2014
- Country
- BRKL United States
- NTLA United States
- Employees
- BRKL N/A
- NTLA N/A
- Industry
- BRKL Savings Institutions
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BRKL Finance
- NTLA Health Care
- Exchange
- BRKL Nasdaq
- NTLA Nasdaq
- Market Cap
- BRKL 1.0B
- NTLA 959.4M
- IPO Year
- BRKL 1998
- NTLA 2016
- Fundamental
- Price
- BRKL $12.00
- NTLA $9.50
- Analyst Decision
- BRKL Buy
- NTLA Buy
- Analyst Count
- BRKL 3
- NTLA 17
- Target Price
- BRKL $14.17
- NTLA $53.00
- AVG Volume (30 Days)
- BRKL 827.1K
- NTLA 3.0M
- Earning Date
- BRKL 01-29-2025
- NTLA 02-20-2025
- Dividend Yield
- BRKL 4.50%
- NTLA N/A
- EPS Growth
- BRKL N/A
- NTLA N/A
- EPS
- BRKL 0.83
- NTLA N/A
- Revenue
- BRKL $333,825,000.00
- NTLA $43,086,000.00
- Revenue This Year
- BRKL N/A
- NTLA $52.50
- Revenue Next Year
- BRKL $39.48
- NTLA $0.42
- P/E Ratio
- BRKL $14.47
- NTLA N/A
- Revenue Growth
- BRKL 1.47
- NTLA N/A
- 52 Week Low
- BRKL $8.01
- NTLA $9.25
- 52 Week High
- BRKL $13.15
- NTLA $34.87
- Technical
- Relative Strength Index (RSI)
- BRKL 53.31
- NTLA 27.36
- Support Level
- BRKL $11.78
- NTLA $9.25
- Resistance Level
- BRKL $12.16
- NTLA $10.39
- Average True Range (ATR)
- BRKL 0.29
- NTLA 0.68
- MACD
- BRKL 0.04
- NTLA -0.16
- Stochastic Oscillator
- BRKL 85.05
- NTLA 6.11
About BRKL Brookline Bancorp Inc.
Brookline Bancorp Inc operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.